Stockreport

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms G azyva has the potential to become a new standard of care for people living w [Read more]